EP2968479B1 - Therapeutic acid ceramidase compositions and methods of making and using them - Google Patents

Therapeutic acid ceramidase compositions and methods of making and using them Download PDF

Info

Publication number
EP2968479B1
EP2968479B1 EP14775400.6A EP14775400A EP2968479B1 EP 2968479 B1 EP2968479 B1 EP 2968479B1 EP 14775400 A EP14775400 A EP 14775400A EP 2968479 B1 EP2968479 B1 EP 2968479B1
Authority
EP
European Patent Office
Prior art keywords
ceramidase
acid
precursor
mixture
inactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14775400.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2968479A4 (en
EP2968479A1 (en
Inventor
Edward H. Schuchman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Priority to PL14775400T priority Critical patent/PL2968479T3/pl
Priority to EP19183045.4A priority patent/EP3659619A1/en
Publication of EP2968479A1 publication Critical patent/EP2968479A1/en
Publication of EP2968479A4 publication Critical patent/EP2968479A4/en
Application granted granted Critical
Publication of EP2968479B1 publication Critical patent/EP2968479B1/en
Priority to HRP20191361 priority patent/HRP20191361T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)

Definitions

  • This invention relates to therapeutic acid ceramidase compositions and methods of making and using them.
  • Acid ceramidase (“AC;” N -acylsphingosine deacylase, I.U.B.M.B. Enzyme No. EC 3.5.1.23) is the most extensively studied member of the ceramidase enzyme family.
  • the protein has been purified from several sources, and the human and mouse cDNAs and genes have been obtained ( Bernardo et al., "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase," J. Biol. Chem. 270:11098-102 (1995 ); Koch et al., "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase.
  • Ceramide is a signaling lipid that is produced in response to various stimuli and extrinsic factors, including serum deprivation and treatment with many chemotherapy drugs, as well as in many human diseases ( Hannun, "Function of Ceramide in Coordinating Cellular Responses to Stress,” Science 274:1855-9 (1996 ); Spiegel et al., “Signal Transduction Through Lipid Second Messengers,” Curr. Opin. Cell. Biol. 8:159-67 (1996 )).
  • ceramide can influence growth and differentiation, regulate protein secretion, induce DNA fragmentation and apoptosis, and increase the synthesis and secretion of cytokines.
  • ceramide is rapidly produced at the cell surface, leading to membrane re-organization and downstream signaling that results in apoptosis.
  • AC and/or other ceramidases may then hydrolyze ceramide into the individual fatty acid and sphingosine components ( Gatt, "Enzymic Hydrolysis and Synthesis of Ceramide,” J. Biol. Chem. 238:3131-3 (1963 ); Gatt, "Enzymatic Hydrolysis of Sphingolipids. 1. Hydrolysis and Synthesis of Ceramides by an Enzyme from Rat Brain,” J. Biol. Chem.
  • SIP sphingosine-1-phosphate
  • AC activity is regulated is the cleavage of the inactive precursor polypeptide into the active enzyme consisting of an alpha and beta subunit linked via disulfide bonds ( Shtraizent et al., "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase,” J. Biol. Chem. 283:11253-11259 (2008 )). It has previously been shown that recombinant AC produced in Chinese Hamster ovary (“CHO”) cells and secreted into the media is a mixture of inactive precursor and active (cleaved) enzyme ( He et al., “Purification and Characterization of Recombinant, Human Acid Ceramidase,” J. Biol. Chem. 278:32978-32986 (2003 )).
  • the present invention is directed to overcoming these and other deficiencies in the art.
  • a first aspect of the present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier.
  • the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase, wherein the ceramidase mixture has no detectable acid sphingomyelinase activity.
  • a method of acid ceramidase treatment including formulating the acid ceramidase used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase.
  • a second aspect of the present invention relates to a method of producing a therapeutic composition.
  • the method includes providing a medium containing an inactive acid ceramidase precursor and incubating the medium under conditions effective to transform a portion of the inactive acid ceramidase precursor to active acid ceramidase through autoproteolytic cleavage, wherein said incubating is carried out at a pH of 4 to 6.5 and a temperature of 30°C, 35°C or 37°C for 3 hours, and further comprises heating said medium under conditions effective to remove acid sphingomyelinase activity.
  • the incubated medium is recovered as a recombinant ceramidase mixture comprising the inactive acid ceramidase precursor and an active acid ceramidase, wherein the ceramidase mixture has no detectable acid sphingomyelinase activity.
  • the present invention describes an optimal composition of recombinant AC (rAC).
  • the present invention further describes the novel finding that, contrary to expectation, the fully active form of the enzyme is not the best form for promoting cell survival. Rather, preparations of purified rAC with higher amounts of inactive acid ceramidase (AC) precursor versus processed active AC are more effective at promoting cell survival and/or improving cell phenotype.
  • Two preparations of recombinant AC were obtained containing different ratios of precursor and active enzyme. They were then used to evaluate the effects on the survival of oocytes in culture. Contrary to expectation, the preparation containing a higher ratio of inactive precursor had a greater effect on cell survival.
  • rAC is being used experimentally in a number of cell systems and animal models to slow ceramide-related cell death and/or improve the phenotype of cells used for cell transplantation. It is also being studied in several disease models.
  • the present invention describes the optimal preparation of rAC to be used for these purposes, which has numerous potential practical implications ( e.g ., in vitro fertilization, cartilage repair, and cystic fibrosis treatment).
  • a first aspect of the present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier.
  • the ceramidase mixture includes an inactive AC precursor and an active AC, wherein the ceramidase mixture has no detectable acid sphingomyelinase activity.
  • Ceramidases hydrolyze the amide linkage of ceramides to generate free fatty acids and sphingoid bases ( Nikolova-Karakashian et al., "Ceramidases,” Methods Enzymol. 311:194-201 (2000 ); Hassler et al., “Ceramidases: Enzymology and Metabolic Roles,” Adv. Lipid Res. 26:49-57 (1993 ) There are three types of ceramidases described to date ( Nikolova-Karakashian et al., “Ceramidases,” Methods Enzymol. 311:194-201 (2000 )). These are classified as acid, neutral, and alkaline ceramidases according to their pH optimum of enzymatic activity.
  • ACs have optimal enzymatic activity at a pH ⁇ 5.
  • the human AC was the first ceramidase to be cloned ( Koch et al., "Molecular Cloning and Characterization of a Full-Length Complementary DNA Encoding Human Acid Ceramidase. Identification Of the First Molecular Lesion Causing Farber Disease," J. Biol. Chem. 271:33110-33115 (1996 )). It is localized in the lysosome and is mainly responsible for the catabolism of ceramide.
  • Inactive AC precursors and active ACs suitable for use in the ceramidase mixtures of this and all aspects of the present invention can be homologous (i.e., derived from the same species) or heterologous (i.e., derived from a different species) to the tissue, cells, and/or subject being treated.
  • Ceramidase (e . g ., AC) precursor proteins undergo autoproteolytic cleavage into the active form (composed of ⁇ - and ⁇ -subunits). The mechanism of human AC cleavage and activation is reported in Shtraizent et al., "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase," J. Biol. Chem.
  • ceramidase as used herein includes both active ceramidases and ceramidase precursor proteins, where ceramidase precursor proteins are converted into active ceramidase proteins through autoproteolytic cleavage.
  • Embodiments in which the precursor protein is taken up by the cell of interest and converted into active ceramidase thereby, as well as embodiments in which the precursor protein is converted into active ceramidase by a different cell or agent (present, for example, in a culture medium), are both contemplated.
  • AC ( N -acylsphingosine deacylase, I.U.B.M.B. Enzyme No. EC 3.5.1.23) protein has been purified from several sources, and the human and mouse cDNAs and genes have been obtained. See Bernardo et al., "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase," J. Biol. Chem. 270:11098-102 (1995 ); Koch et al., "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase. Identification of the First Molecular Lesion Causing Farber Disease," J. Biol. Chem.
  • AC protein [ Homo sapien ] (Accession No. AAC50907) is shown below in SEQ ID NO: 1.
  • the AC alpha subunit begins at the amino acid at position 22 and continues through position 142 (as shown in bold in SEQ ID NO: 1), while the beta subunit of the AC begins with the amino acid at position 143 and continues through position 395 (as shown in italics in SEQ ID NO: 1).
  • Active ACs and inactive AC precursor proteins that can be used in this and all aspects of the present invention include, without limitation, those set forth in Table 1 below.
  • Table 1 Exemplary Acid Ceramidase Family Members Homo sapiens Caenorhabditis elegans UniProt Q13510, Q9H715, Q96AS2 UniProt 045686 OMIM 228000 IntAct 045686 NCBI Gene 427 NCBI Gene 173120 NCBI RefSeq NP_808592, NP_004306 NCBI RefSeq NP_493173 NCBI RefSeq NM_177924, NM_004315 NCBI RefSeq NM_060772 NCBI UniGene 427 NCBI UniGene 173120 NCBI Accession Q13510, AAC73009, AAC50907 NCBI Accession O45686, CAB0 5556 Mus musculus Danio rerio UniProt Q9WV54, Q3U8A7, Q78P93
  • the ceramidase mixture of the therapeutic composition may, in some embodiments, contain a greater amount of the inactive AC precursor than active AC. Alternatively, the ceramidase mixture of the therapeutic composition may, in some instances, contain a lesser amount of inactive AC precursor than active AC.
  • an effective amount of the inactive AC precursor compared to the active AC in the mixture ranges from about 5 to 95 wt% of the inactive AC precursor and 95 to 5 wt% of the active AC; 20 to 80 wt% of the inactive AC precursor and 80 to 20 wt% of the active AC; 30 to 70 wt% of the inactive AC precursor and 70 to 30 wt% of the active AC; 40 to 60 wt% of the inactive AC precursor and 60 to 40 wt% of the active AC; 55 to 95 wt% of the inactive AC precursor and 45 to 5 wt% of the active AC; 70 to 95 wt% of the inactive AC precursor and 30 to 5 wt% of the active AC; and may alternatively range from 80 to 90 wt% of the inactive AC precursor and 20 to 10 wt% of the active AC.
  • an effective amount of the inactive AC precursor is 90 wt% while the active ceramidase is 10 wt% of the mixture.
  • An alternative embodiment may include 80 wt% of the inactive ceramidase precursor and 20 wt% of the active AC in the ceramidase mixture.
  • the ceramidase mixture may contain 60 wt% inactive ceramidase precursor and 40 wt% active ceramidase.
  • the therapeutic composition may also include pharmaceutically acceptable adjuvants, excipients, and/or stabilizers, and can be in solid or liquid form, such as tablets, capsules, powders, solutions, suspensions, or emulsions.
  • Suitable adjuvants include, but are not limited to, flagellin, Freund's complete or incomplete adjuvant, aluminum hydroxide, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsion, dinitrophenol, iscomatrix, and liposome polycation DNA particles.
  • a method of AC treatment including formulating the AC used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive AC precursor and an active AC.
  • Treatment according to this aspect is carried out using methods that will be apparent to the skilled artisan.
  • AC acid Ceramidase and Human Disease
  • Zeidan et al. "Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy," Curr. Drug Targets 9(8):653-661 (2008 )).
  • treatment is carried out by introducing a ceramidase protein into the cells.
  • proteins or polypeptide agents e . g ., active ceramidase, inactive ceramidase precursor proteins
  • conjugation of the desired protein or polypeptide involves the conjugation of the desired protein or polypeptide to a polymer that is stabilized to avoid enzymatic degradation of the conjugated protein or polypeptide.
  • Conjugated proteins or polypeptides of this type are described in U.S. Patent No. 5,681,811 to Ekwuribe .
  • the chimeric protein can include a ligand domain and the polypeptide agent (e.g., rAC, active AC, other ceramidase, inactive AC precursor protein, other ceramidase precursor proteins).
  • the ligand domain is specific for receptors located on a target cell.
  • Further embodiments of the present aspect relate to methods of treatment for a certain disease or disorder. These methods involve formulating the AC used in the treatment as a ceramidase mixture including an inactive ceramidase precursor and an active AC.
  • the disease or disorder is a joint disease or disorder and the ceramidase mixture according to the methods is administered to a subject to treat the subject for the joint disease or disorder.
  • exemplary types of joint disease or disorders include, without limitation, osteoarthritis, rheumatoid arthritis, mucopolysaccharidosis, degenerative joint disease, joint injury, and Farber lipogranulomatosis.
  • the disease or disorder is a neurodegenerative disease or disorder and the ceramidase mixture according to the methods is administered to a subject to treat the subject for the neurodegenerative disease or disorder.
  • neurodegenerative diseases or disorders include, without limitation, Alzheimer's disease, Frontotemporal Dementia, Dementia with Lewy Bodies, Prion disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, amyotrophic lateral sclerosis, inclusion body myositis, degenerative myopathy, spinocerebellar atrophy, metabolic neuropathy, diabetic neuropathy, endocrine neuropathy, orthostatic hypotension, brain injury, spinal cord injury, stroke, and motor neuron diseases such as spinal muscular atrophy.
  • the disease or disorder is a cardiac disease or disorder and the ceramidase mixture according to the methods is administered to a subject to treat the subject for the cardiac disease or disorder.
  • cardiac diseases or disorders include, without limitation, heart disease, cardiac injury, atherosclerosis, thrombosis, cardiomyocyte apoptosis, hypercardia, heart infarction, mitral regurgitation, aortic regurgitation, septal defect, and tachycardia-bradycardia syndrome.
  • the disease or disorder is diabetes and the ceramidase mixture according to the methods is administered to a subject to treat the subject for diabetes.
  • the disease or disorder is a pathogenic infection in a subject having cystic fibrosis, chronic obstructive pulmonary disease (COPD), and/or an open wound, and the ceramidase mixture according to the methods is administered to a subject to treat the subject for the pathogenic infection.
  • pathogenic infections include, without limitation, viral, fungal, prionic, and bacterial.
  • Subjects suffering from cystic fibrosis, COPD, and/or an open wound may possess a high susceptibility for acquiring acute and/or chronic pathogenic infections, such as, e.g., bacterial, viral, fungal, protozoan, and/or prionic pathogenic infections.
  • Bacterial pathogens include, without limitation, Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, Chlamydia trachomatis, Clostridium botulinum, Clostridium tetani, Corynebacterium dipththeriae , Escherichia coli, enterohemorrhagic E. coli, enterotoxigenic E.
  • Viral pathogens include, without limitation, RNA viruses, DNA viruses, adenovirdiae (e . g ., mastadenovirus and aviadeno virus), herpesviridae ( e . g ., herpes simplex virus 1, herpes simplex virus 2, herpes simplex virus 5, and herpes simplex virus 6), leviviridae ( e . g ., levivirus, enterobacteria phage MS2, allolevirus), poxyiridae ( e .
  • adenovirdiae e . g ., mastadenovirus and aviadeno virus
  • herpesviridae e . g ., herpes simplex virus 1, herpes simplex virus 2, herpes simplex virus 5, and herpes simplex virus 6
  • leviviridae e . g ., levivirus, enterobacteria phage MS2, allo
  • chordopoxyirinae parapoxvirus
  • avipoxvirus capripoxvirus
  • leporipoxvirus suipoxvirus
  • molluscipox virus entomopoxyirinae
  • papovaviridae e . g ., polyomavirus and papillomavirus
  • paramyxoviridae e . g ., paramyxovirus, parainfluenza virus 1
  • mobillivirus such as measles virus, rubulavirus (such as mumps virus)
  • pneumonoviridae e .
  • pneumovirus human respiratory syncytial virus
  • metapneumovirus e . g ., avian pneumovirus and human metapneumo virus
  • picornaviridae e . g ., enterovirus, rhinovirus, hepatovirus such as human hepatitis A virus, cardiovirus, and apthovirus
  • reoviridae e . g ., orthoreo virus, orbivirus, rotavirus, cypo virus, fijivirus, phytoreo virus, and oryzavirus
  • retroviridae e .
  • mammalian type B retroviruses mammalian type C retroviruses, avian type C retroviruses, type D retrovirus group
  • BLV-HTLV retroviruses lentivirus (such as human immunodeficiency virus 1 and human immunodeficiency virus 2; and spuma virus)
  • flaviviridae e . g ., hepatitis C virus
  • hepadnaviridae e . g ., hepatitis B virus
  • togaviridae e . g ., alphavirus - such as Sindbis virus and rubivirus, such as rubella virus
  • rhabdoviridae e .
  • vesiculovirus e.g ., vesiculovirus, lyssavirus, ephemera virus, cytorhabdovirus, and necleorhabdovirus
  • arenaviridae e . g ., arenavirus, lymphocytic choriomeningitis virus, Ippy virus, and lassa virus
  • coronaviridae e .
  • coronavirus and torovirus Cytomegalovirus (mononucleosis), Dengue virus (dengue fever, shock syndrome), Epstein-Barr virus (mononucleosis, Burkitt's lymphoma), Human T-cell lymphotropic virus type 1 (T-cell leukemia), Influenza A, B, and C (respiratory disease), Japanese encephalitis virus (pneumonia, encephalopathy), Poliovirus (paralysis), Rhinovirus (common cold), Rubella virus (fetal malformations), Vaccinia virus (generalized infection), Yellow fever virus (jaundice, renal and hepatic failure), and Varicella zoster virus (chickenpox).
  • Cytomegalovirus monoonucleosis
  • Dengue virus dengue fever, shock syndrome
  • Epstein-Barr virus monoonucleosis, Burkitt's lymphoma
  • Human T-cell lymphotropic virus type 1 T-cell leukemia
  • Pathogenic fungi include, without limitation, the genera Aspergillus (e . g ., Aspergillus fumigates), Blastomyces, Candida ( e . g ., Candida albicans), Coccidiodes, Cryptococcus, Histoplasma, Phycomyces, Tinea corporis, Tinea unguis, Sporothrix schenckii, and Pneumocystis carinii.
  • Pathogenic protozoan include, without limitation, Trypanosome spp., Leishmania spp., Plasmodium spp., Entamoeba spp., and Giardia spp. such as Giardia lamblia.
  • an "open wound” refers to a type of injury in which an epithelial layer, i.e., skin, is torn, cut, and/or punctured.
  • an open wound refers to a sharp injury which damages the dermis of the skin and concomitantly increases the chance of acquiring an infection.
  • the term "open wound” also encompasses burns.
  • the disease or disorder is an infection caused by ceramide accumulation and the ceramidase mixture according to the methods is administered to a subject to treat the subject for the ceramide accumulation infection.
  • the methods may, in other embodiments, be used to treat Farber disease.
  • treatment is carried out in vitro.
  • a ceramidase mixture can be taken from the subject or from a second subject then administered to the first subject ( e . g ., by injecting the mixture into the first subject).
  • treatment is carried out in vivo.
  • Mammalian subjects include, for example, human subjects, equine subjects, porcine subjects, feline subjects, and canine subjects. Human subjects are particularly preferred.
  • any combination of active ceramidase, ceramidase precursor protein, and/or nucleic acid encoding ceramidase/ceramidase precursor protein can be administered.
  • Administration can be accomplished either via systemic administration to the subject or via targeted administration to affected tissues, organs, and/or cells.
  • the ceramidase mixture may be administered to a non-targeted area along with one or more agents that facilitate migration of the ceramidase mixture to (and/or uptake by) a targeted tissue, organ, or cell.
  • the ceramidase mixture itself can be modified to facilitate its transport to (and uptake by) the desired tissue, organ, or cell, as will be apparent to one of ordinary skill in the art.
  • the ceramidase mixture will be administered to a subject in a vehicle that delivers the ceramidase to the target cell, tissue, or organ.
  • routes of administration include, without limitation, orally, by inhalation, intratracheal inoculation, aspiration, airway instillation, aerosolization, nebulization, intranasal instillation, oral or nasogastric instillation, intraperitoneal injection, intravascular injection, topically, transdermally, parenterally, subcutaneously, intravenous injection, intra-arterial injection (such as via the pulmonary artery), intramuscular injection, intrapleural instillation, intraventricularly, intralesionally, intrathecally, by application to mucous membranes (such as that of the nose, throat, bronchial tubes, genitals, and/or anus), or implantation of a sustained release vehicle.
  • mucous membranes such as that of the nose, throat, bronchial tubes, genitals, and/or anus
  • the ceramidase mixture is administered orally, topically, intranasally, intraperitoneally, intravenously, subcutaneously, or by aerosol inhalation. In some embodiments, the ceramidase mixture is administered via aerosol inhalation. In some embodiments, the ceramidase mixture can be incorporated into pharmaceutical compositions suitable for administration, as described herein.
  • the ceramidase mixture may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or may be incorporated directly with the food of the diet.
  • the ceramidase mixture may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like.
  • Such compositions and preparations should contain at least 0.1% of ceramidase.
  • the percentage of ceramidase mixture in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
  • the amount of the ceramidase mixture in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • the tablets, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, or alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin.
  • a binder such as gum tragacanth, acacia, corn starch, or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, or alginic acid
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose, or saccharin.
  • a liquid carrier such as fatty oil.
  • the ceramidase mixture may also be administered parenterally.
  • Solutions or suspensions of ceramidase can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
  • Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • the ceramidase mixture may also be administered directly to the airways in the form of an aerosol.
  • ceramidase in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • the ceramidase mixture may also be administered in a non-pressurized form.
  • Exemplary delivery devices include, without limitation, nebulizers, atomizers, liposomes (including both active and passive drug delivery techniques) ( Wang et al., "pH-Sensitive Immunoliposomes Mediate Target-cell-specific Delivery and Controlled Expression of a Foreign Gene in Mouse," Proc. Nat'l Acad. Sci. USA 84:7851-5 (1987 ); Bangham et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J. Mol. Biol. 13:238-52 (1965 ); U.S. Patent No. 5,653,996 to Hsu ; U.S. Patent No. 5,643,599 to Lee et al.
  • Administration can be carried out as frequently as required and for a duration that is suitable to provide effective treatment.
  • administration can be carried out with a single sustained-release dosage formulation or with multiple daily doses.
  • Treatment may be carried out in vitro or in vivo.
  • In vivo treatments include, for example, embodiments in which the population of cells is present in a mammalian subject.
  • the population of cells can be either autologous (produced by the subject), homologous, or heterologous.
  • Suitable subjects according to these embodiments include mammals, e . g ., human subjects, equine subjects, porcine subjects, feline subjects, and canine subjects.
  • one or more additional agents which reduce ceramide levels may be administered with the ceramidase mixture.
  • acid sphingomyelinase e . g ., amitryptiline ( Becker et al., "Acid Sphingomyelinase Inhibitors Normalize Pulmonary Ceramide and
  • the effective amount of a therapeutic agent/cell population administered to the subject will depend on the type and severity of the disease or disorder and on the characteristics of the individual, such as general health, age, sex, body weight, and tolerance to drugs. It will also depend on the degree, severity, and type of disease or disorder. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • the method includes treating one or more mammalian cells ex vivo with said ceramidase mixture to promote cell survival.
  • Cells whose survival can be promoted according to this aspect include, without limitation, those that utilize the ceramidase apoptosis pathway, which includes a wide variety of cells ( Obeid et al., "Programmed Cell Death Induced by Ceramide,” Science 259:1769-71 (1993 )), e . g ., hepatocytes ( Arora et al., "Ceramide Induces Hepatocyte Cell Death Through Disruption of Mitochondrial Function in the Rat," Hepatol.
  • lymphocytes Gombos et al., "Cholesterol and Sphingolipids as Lipid Organizers of the Immune Cells' Plasma Membrane: Their Impact on the Functions of MHC Molecules, Effector T-lymphocytes and T-cell Death," Immunol. Lett. 104(1-2):59-69 (2006 )
  • eggs, embryos, neurons, sperm, synovial fibroblasts, and embryonic stem cells are eggs (fertilized or unfertilized), embryos, primary cells (e.g., neurons), sperm, synovial fibroblasts, and embryonic stem cells.
  • ceramide apoptosis pathway appears to be conserved across mammalian species ( Lee & Amoscato, "TRAIL and Ceramide,” Vitam. Horm. 67:229-55 (2004 ); see also , Samadi, “Ceramide-induced Cell Death in Lens Epithelial Cells," Mol. Vis. 13:1618-26 (2007 ) (humans); Parra et al., “Changes in Mitochondrial Dynamics During Ceramide-induced Cardiomyocyte Early Apoptosis,” Cardiovasc. Res.
  • suitable cells include those of humans, monkeys, mice, rats, guinea pigs, cows, horses, sheep, pigs, dogs, and cats. This method may also be used to prolong the survival of eggs and/or embryos during in vitro fertilization procedures, facilitating the identification and selection of healthy embryos for reimplantation, especially for older human women and for veterinary breeding procedures.
  • Cells according to this aspect can be provided by methods that will be apparent to the skilled artisan.
  • the cells can be obtained from an animal or from an existing ex vivo source (e . g ., a tissue sample, a cell culture, etc.) using standard techniques.
  • Treating cells ex vivo includes treating cells present in a homogeneous culture, as well as cells present in a heterogeneous culture ( e . g ., a tissue sample).
  • Inactive AC precursors and active ACs that can be used to prepare the ceramidase mixture in this and all aspects of the present invention include, without limitation, those set forth in Table 1, supra.
  • the AC can be homologous (i.e., derived from the same species) or heterologous (i.e., derived from a different species) to the one or more cells being treated.
  • One embodiment of the present aspect of AC treatment relates to a method of producing chondrocytes with the ceramidase mixture. This method involves selecting a population of cells having the potential to differentiate into chondrocytes and treating the selected cell population with the ceramidase mixture to transform one or more of the cells in the selected population into chondrocytes.
  • Cells having the potential to differentiate into chondrocytes include bone marrow cells, fibroblasts, mesenchymal stem cells, and/or fibroblasts ( see Mizushima et al., "Ceramide, a Mediator of Interleukin 1, Tumour Necrosis Factor ⁇ , as Well as Fas Receptor Signaling, Induces Apoptosis of Rheumatoid Arthritis Synovial Cells," Ann. Rheum. Dis. 57:495-9 (1998 )).
  • Chondrocytes include, without limitation, articular chondrocytes, nasal chondrocytes, tracheal chondrocytes, meniscal chondrocytes, and aural chondrocytes. These include, for example, mammalian chondrocytes, e . g ., human chondrocytes, equine chondrocytes, porcine chondrocytes, feline chondrocytes, and canine chondrocytes.
  • the chondrocytes are primary chondrocytes.
  • Suitable cells include mammalian cells, e . g ., human cells, equine cells, porcine cells, feline cells, and/or canine cells. Human cells are particularly preferred.
  • the ceramidase mixture and methods of treating the populations of cells with ceramidase mixture include all those set forth supra.
  • Another embodiment of the present aspect of AC treatment relates to a method of promoting chondrogenesis with the ceramidase mixture.
  • this method further includes selecting a population of stem cells in need of differentiation into chondrocytes, treating the population of stem cells with the ceramidase mixture to enrich mesenchymal stem cells within the stem cell population, and treating the population of enriched mesenchymal stem cells with the ceramidase mixture to promote differentiation of mesenchymal stem cells into chondrocytes.
  • Suitable cells populations include mammalian cells populations, e . g ., human cells populations, equine cells populations, porcine cells populations, feline cells populations, and/or canine cells populations. Human cells populations are particularly preferred.
  • Suitable stem cells include bone marrow cells, adipocytes, and skin cells. Additional stem cells according to this aspect include, without limitation, embryonic stem cells, somatic stem cells, induced pluripotent stem cells, totipotent stem cells, pluripotent stem cells, and multipotent stem cells. Exemplary stem cells include, for example, hematopoietic stem cells, mesenchymal stem cells, neural stem cells, endothelial progenitor cells, epithelial stem cells, epidermal stem cells, adipocytes, and cardiac stem cells. Suitable stem cells include, but are not limited to, mammalian cells, e . g ., human, equine, porcine, feline, and canine bone marrow cells, adipocytes, and skin cells. Human cells are particularly preferred.
  • the differentiated mesenchymal stem cells may, alternatively, be primary cells such as, but not limited to, neurons, hepatocytes, bone cells, lung cells, and cardiac cells.
  • the number of differentiated cells in the cell population is maintained. In at least one embodiment, the number of differentiated cells in the cell population is increased. As will be apparent to the skilled artisan, maintaining or increasing the overall number of differentiated cells in the population can be achieved by decreasing or preventing de-differentiation of cells in the population that are already differentiated, by stimulating the differentiation of undifferentiated cells in the population, or both.
  • the ceramidase mixture and methods of treating the populations of cells with ceramidase mixture include all those set forth supra.
  • a second aspect of the present invention relates to a method of producing a therapeutic composition.
  • the method includes providing a medium containing an inactive AC precursor; incubating the medium under conditions effective to transform a portion of the inactive AC precursor to active AC through autoproteolytic cleavage, wherein said incubating is carried out at a pH of 4 to 6.5 and a temperature of 30°C, 35°C or 37°C for 3 hours, and further comprises heating said medium under conditions effective to remove acid sphingomyelinase activity; and recovering the incubated medium as a recombinant ceramidase mixture comprising the inactive AC precursor and an active AC, wherein the ceramidase mixture has no detectable acid sphingomyelinase activity.
  • the therapeutic composition of the present invention contains a recombinant protein including both inactive AC precursor and active AC.
  • the recombinant protein of the present invention may be prepared for use in the above described methods of the present invention using standard methods of synthesis known in the art, including solid phase peptide synthesis (Fmoc or Boc strategies) or solution phase peptide synthesis.
  • proteins of the present invention may be prepared using recombinant expression systems.
  • the use of recombinant expression systems involves inserting the nucleic acid molecule encoding the amino acid sequence of the desired peptide into an expression system to which the molecule is heterologous (i.e., not normally present).
  • One or more desired nucleic acid molecules encoding a peptide of the invention may be inserted into the vector.
  • the multiple nucleic acid molecules may encode the same or different peptides.
  • the heterologous nucleic acid molecule is inserted into the expression system or vector in proper sense (5' ⁇ 3') orientation relative to the promoter and any other 5' regulatory molecules, and correct reading frame.
  • nucleic acid constructs can be carried out using standard cloning procedures well known in the art as described by Joseph Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989 ).
  • U.S. Patent No. 4,237,224 to Cohen and Boyer describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation into a suitable host cell.
  • a variety of genetic signals and processing events that control many levels of gene expression can be incorporated into the nucleic acid construct to maximize peptide production.
  • DNA transcription and messenger RNA (“mRNA”) translation can be incorporated into the nucleic acid construct to maximize peptide production.
  • mRNA messenger RNA
  • any one of a number of suitable promoters may be used. For instance, when cloning in E.
  • promoters such as the T7 phage promoter, lac promoter, trp promoter, rec A promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lac UV5, omp F, bla , lpp , and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lac UV5 ( tac ) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
  • promoters such as the T7 phage promoter, lac promoter, trp promoter, rec A promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lac UV5, omp F, bla , lpp , and the like, may be used to direct high levels of transcription of
  • Common promoters suitable for directing expression in mammalian cells include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.
  • Mammalian cells that may be used for manufacture of the recombinant protein of the present invention include, for example, Chinese Hamster Ovary (CHO) cells, plant cells, chicken eggs, and human fibroblasts.
  • initiation signals required for efficient gene transcription and translation in prokaryotic cells that can be included in the nucleic acid construct to maximize peptide production.
  • suitable transcription and/or translation elements including constitutive, inducible, and repressible promoters, as well as minimal 5' promoter elements, enhancers or leader sequences may be used.
  • Roberts and Lauer "Maximizing Gene Expression On a Plasmid Using Recombination In Vitro," Methods in Enzymology 68:473-82 (1979 ).
  • a nucleic acid molecule encoding a recombinant protein of the present invention, a promoter molecule of choice, including, without limitation, enhancers, and leader sequences; a suitable 3' regulatory region to allow transcription in the host, and any additional desired components, such as reporter or marker genes, are cloned into the vector of choice using standard cloning procedures in the art, such as described in Joseph Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989 ); Frederick M. Ausubel, SHORT PROTOCOLS IN MOLECULAR BIOLOGY (Wiley 1999 ), and U.S. Patent No. 4,237,224 to Cohen and Boyer .
  • nucleic acid molecule encoding the peptide Once the nucleic acid molecule encoding the peptide has been cloned into an expression vector, it is ready to be incorporated into a host. Recombinant molecules can be introduced into cells, without limitation, via transfection (if the host is a eukaryote), transduction, conjugation, mobilization, or electroporation, lipofection, protoplast fusion, mobilization, or particle bombardment, using standard cloning procedures known in the art, as described by JOSEPH SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989 ).
  • host-vector systems may be utilized to express the recombinant protein or polypeptide.
  • the vector system must be compatible with the host used.
  • Host-vector systems include, without limitation, the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e . g ., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus ( e . g ., baculovirus); and plant cells infected by bacteria.
  • Purified peptides may be obtained by several methods readily known in the art, including ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, gel filtration, and reverse phase chromatography.
  • the peptide is preferably produced in purified form (preferably at least about 80% or 85% pure, more preferably at least about 90% or 95% pure) by conventional techniques.
  • purified form preferably at least about 80% or 85% pure, more preferably at least about 90% or 95% pure
  • the peptide can be isolated and purified by centrifugation (to separate cellular components from supernatant containing the secreted peptide) followed by sequential ammonium sulfate precipitation of the supernatant.
  • cells may be transformed with DNA encoding AC and then cultured under conditions effective to produce the medium containing inactive AC precursor.
  • the fraction containing the peptide is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the peptides from other proteins. If necessary, the peptide fraction may be further purified by other chromatography.
  • the incubation is carried out under conditions effective to reduce the transformation rate of inactive AC precursor to active AC compared to the transformation rate achieved when said incubating is carried out at a pH of 4 and a temperature of 4°C or 37°C, for 24 hours, under otherwise consistent conditions.
  • the ceramidase mixture during the incubating has a pH 4.0 to 6.5.
  • the mixture may, for example, have a pH of 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5.
  • the temperature of the ceramidase mixture during said incubating is 30 °C, 35 °C, or 37 °C.
  • the mixture may be incubated under conditions of 37 °C with a pH of 4.0.
  • the mixture is incubated for a period of 3 hours.
  • the medium may be heated under conditions effective to remove acid sphingomyelinase activity.
  • the medium may be heated to 60 °C for a period of time including, but not limited to, less than 20 minutes, 20-40 minutes, 40-60 minutes, or more than 60 minutes.
  • rAC (Lot 6 and Lot 7) - Chinese hamster ovary cells overexpressing the human Asah1 gene were generated and rAC was purified from the media ( He et al., "Purification and Characterization of Recombinant, Human Acid Ceramidase. Catalytic Reactions and Interactions With Acid Sphingomyelinase," J. Biol. Chem. 278:32978-32986 (2003 )). No in vitro manipulation was carried out after purification of Lot 6 (higher amount of inactive AC precursor). After purification of Lot 7 enzyme, the rAC was incubated in pH 4 citrate phosphate buffer at 37°C for three hours.
  • Example 2 - rAC With Less Active AC Perform Better than Those With More Active AC.
  • Figure 1B summarizes results for ability to form healthy mouse embryos in Lot 6 and Lot 7.
  • Lot 7 (containing more active rAC) produced more apoptotic embryos than lot 6 (containing less active rAC).
  • the preparation with less active enzyme (Lot 6) provided better results in IVF (fewer apoptotic embryos). This was unexpected.
  • Lot 6 and Lot 7 were also tested using cultured rat chondrocytes ( Figure 1C ). At two weeks the amount of collagen 2 expression was analyzed using western blotting. Cells cultured with Lot 7 (more active rAC) produced less collagen 2. Lot 6 was better in maintaining the chondrocyte phenotype after expansion ( Figure 1C , based on the expression of collagen 2). This was unexpected.
  • the improved performance of rAC containing less active AC is hypothesized to be due to the shorter half-life of the active enzyme in cultured cells (conversely the longer half-life of the precursor).
  • ASM contaminating acid sphingomyelinase activity
  • Conditioned media (DMEM, pH 6.8 containing 10% fetal calf serum) was collected from Chinese hamster ovary cells overexpressing and secreting recombinant human acid ceramidase (rhAC) ( He et al., "Purification and Characterization of Recombinant, Human Acid Ceramidase. Catalytic Reactions and Interactions With Acid Sphingomyelinase," J. Biol. Chem. 278:32978-32986 (2003 )). The cells were grown until ⁇ 100% confluency in T-75mm flasks, and media was then collected after 4 days of additional growth. The collected media was filtered through 0.22mm membranes to removed debris and placed in a 37°C incubator for varying lengths of time.
  • rhAC human acid ceramidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
EP14775400.6A 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them Active EP2968479B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL14775400T PL2968479T3 (pl) 2013-03-14 2014-03-13 Kompozycje terapeutyczne ceramidazy kwasowej i sposoby ich wytwarzania i stosowania
EP19183045.4A EP3659619A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
HRP20191361 HRP20191361T1 (hr) 2013-03-14 2019-07-29 Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784594P 2013-03-14 2013-03-14
PCT/US2014/026481 WO2014160390A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19183045.4A Division EP3659619A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them

Publications (3)

Publication Number Publication Date
EP2968479A1 EP2968479A1 (en) 2016-01-20
EP2968479A4 EP2968479A4 (en) 2016-07-27
EP2968479B1 true EP2968479B1 (en) 2019-07-17

Family

ID=51625420

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19183045.4A Pending EP3659619A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
EP14775400.6A Active EP2968479B1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19183045.4A Pending EP3659619A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them

Country Status (14)

Country Link
US (3) US9937246B2 (hr)
EP (2) EP3659619A1 (hr)
JP (4) JP6832158B2 (hr)
CA (1) CA2905449A1 (hr)
DK (1) DK2968479T3 (hr)
ES (1) ES2739811T3 (hr)
HK (1) HK1220399A1 (hr)
HR (1) HRP20191361T1 (hr)
HU (1) HUE046113T2 (hr)
IL (4) IL241390B (hr)
MX (2) MX2015012471A (hr)
PL (1) PL2968479T3 (hr)
PT (1) PT2968479T (hr)
WO (1) WO2014160390A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
EP2753346B1 (en) 2011-09-07 2020-04-22 Mount Sinai School Of Medicine Ceramidase and cell differentiation
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
EP3659619A1 (en) * 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
WO2018132667A1 (en) 2017-01-13 2018-07-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating farber disease
CA3088225A1 (en) 2018-02-02 2019-08-08 Enzyvant Therapeutics Gmbh Methods for treating farber disease
KR20240111011A (ko) * 2018-03-27 2024-07-16 엔지반트 테라퓨틱스 게엠베하 파버병 마커 및 이의 용도
US20210244827A1 (en) * 2018-06-29 2021-08-12 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (hr) 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (hr) 1974-05-02 1978-07-06
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
KR960700036A (ko) 1992-12-30 1996-01-19 조오지 조 레비스 항골양 조성물(anticaries compositions)
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE69407292T2 (de) 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU734290B2 (en) 1997-10-29 2001-06-07 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
JP2003516122A (ja) 1999-10-13 2003-05-13 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｄａｐキナーゼのショートセグメント
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
US20030215435A1 (en) 2000-04-06 2003-11-20 Berent Susan L Expression system for effeiciently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
US7169610B2 (en) 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1649064B1 (en) 2003-07-17 2011-06-01 Pacific Edge Biotechnology Limited Markers for detection of gastric cancer
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
CA2585645C (en) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
JP2008537143A (ja) 2005-04-19 2008-09-11 バーミリオン， インコーポレイテッド アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
US7981399B2 (en) 2006-01-09 2011-07-19 Mcgill University Method to determine state of a cell exchanging metabolites with a fluid medium by analyzing the metabolites in the fluid medium
WO2007089734A2 (en) 2006-01-27 2007-08-09 Eastern Virginia Medical School Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
EP2010551B1 (en) 2006-04-24 2010-09-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
WO2007136635A1 (en) 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
BRPI0713572A2 (pt) 2006-06-20 2012-10-23 Stephen Duguay meios livres de soro e seus usos para expansão de condrócitos
WO2008086296A2 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
WO2008124508A1 (en) 2007-04-06 2008-10-16 Genzyme Corporation Methods of evaluating cells and cell cultures
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
NZ599928A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
FR2924946B1 (fr) 2007-12-18 2010-02-26 Oreal Utilisation cosmetique de proteines de type ceramidase acide
DE102007063535A1 (de) 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
BRPI0914684C1 (pt) 2008-06-26 2021-05-25 Orphazyme As uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
JP5721631B2 (ja) 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
US20120115158A1 (en) 2009-05-01 2012-05-10 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
DK2470199T3 (da) 2009-08-28 2019-08-05 Icahn School Med Mount Sinai Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
HUE045784T2 (hu) 2009-11-27 2020-01-28 Genzyme Corp Eliglusztát (Genz 112638) mint glükozilceramid-szintáz inhibitor Fabry- vagy Gaucher-kór kezelési eljárásában történõ alkalmazásra, az eljárás tartalmazza az egyedi terápiás dózisnak a beteg P-450 metabolizmusához történõ beállítását
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
CN103597356A (zh) 2011-05-10 2014-02-19 先进流体逻辑公司 酶浓缩与分析
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
EP2753346B1 (en) 2011-09-07 2020-04-22 Mount Sinai School Of Medicine Ceramidase and cell differentiation
ES2897825T3 (es) * 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
US9341787B2 (en) 2013-01-02 2016-05-17 Micron Technology, Inc. Apparatus providing simplified alignment of optical fiber in photonic integrated circuits
EP3659619A1 (en) * 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
HUE046113T2 (hu) 2020-02-28
US20180193436A1 (en) 2018-07-12
CA2905449A1 (en) 2014-10-02
JP6832386B2 (ja) 2021-02-24
JP2019150042A (ja) 2019-09-12
DK2968479T3 (da) 2019-08-12
IL272214B (en) 2022-01-01
US9937246B2 (en) 2018-04-10
JP6832158B2 (ja) 2021-02-24
IL288427A (en) 2022-01-01
JP2021042227A (ja) 2021-03-18
US10238721B2 (en) 2019-03-26
US20190231857A1 (en) 2019-08-01
PL2968479T3 (pl) 2019-10-31
EP3659619A1 (en) 2020-06-03
IL241390B (en) 2020-03-31
JP2023015402A (ja) 2023-01-31
IL272214A (en) 2020-03-31
MX2022003486A (es) 2022-04-25
EP2968479A4 (en) 2016-07-27
EP2968479A1 (en) 2016-01-20
IL304629A (en) 2023-09-01
JP2016520519A (ja) 2016-07-14
WO2014160390A1 (en) 2014-10-02
US20160038574A1 (en) 2016-02-11
HK1220399A1 (zh) 2017-05-05
ES2739811T3 (es) 2020-02-04
HRP20191361T1 (hr) 2019-11-01
US10918702B2 (en) 2021-02-16
BR112015024538A2 (pt) 2018-05-08
MX2015012471A (es) 2016-08-03
IL241390A0 (en) 2015-11-30
PT2968479T (pt) 2019-08-07

Similar Documents

Publication Publication Date Title
US10918702B2 (en) Therapeutic acid ceramidase compositions and methods of making and using them
AU2018200710B2 (en) Cells for producing recombinant iduronate-2-sulfatase
US20190321454A1 (en) Ceramidase and cell differentiation
US20230279440A1 (en) Methods to genetically modify cells for delivery of therapeutic proteins
AU2013282417A1 (en) Method of producing recombinant iduronate-2-sulfatase
EP3357489A1 (en) Mutated arylsulfatase a
WO2019060837A1 (en) PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
BR112015024538B1 (pt) Composição terapêutica de ceramidase ácida e seu método de produção
EP4043562A1 (en) Mutated arylsulfatase a with increased stability
EA044790B1 (ru) Клетки для получения рекомбинантной идуронат-2-сульфатазы

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160627

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/50 20060101ALI20160621BHEP

Ipc: A61K 38/43 20060101AFI20160621BHEP

Ipc: A61P 19/04 20060101ALI20160621BHEP

Ipc: A61P 25/28 20060101ALI20160621BHEP

Ipc: C12N 9/78 20060101ALI20160621BHEP

Ipc: A61K 38/46 20060101ALI20160621BHEP

Ipc: A61P 31/00 20060101ALI20160621BHEP

Ipc: A61P 9/00 20060101ALI20160621BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220399

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170614

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190125

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20191361

Country of ref document: HR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2968479

Country of ref document: PT

Date of ref document: 20190807

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014050172

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190807

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TR-IP CONSULTING LLC, CH

Ref country code: AT

Ref legal event code: REF

Ref document number: 1155213

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190815

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190717

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20191361

Country of ref document: HR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191017

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2739811

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200204

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: ROUTE DU COUTSET 18, 1485 NUVILLY (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191117

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191018

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E046113

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191361

Country of ref document: HR

Payment date: 20200226

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014050172

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

26N No opposition filed

Effective date: 20200603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1155213

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190717

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191361

Country of ref document: HR

Payment date: 20210223

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191361

Country of ref document: HR

Payment date: 20220221

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191361

Country of ref document: HR

Payment date: 20230221

Year of fee payment: 10

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191361

Country of ref document: HR

Payment date: 20240221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240327

Year of fee payment: 11

Ref country code: NL

Payment date: 20240326

Year of fee payment: 11

Ref country code: IE

Payment date: 20240327

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240222

Year of fee payment: 11

Ref country code: FI

Payment date: 20240325

Year of fee payment: 11

Ref country code: DE

Payment date: 20240327

Year of fee payment: 11

Ref country code: CZ

Payment date: 20240227

Year of fee payment: 11

Ref country code: GB

Payment date: 20240327

Year of fee payment: 11

Ref country code: PT

Payment date: 20240227

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240327

Year of fee payment: 11

Ref country code: PL

Payment date: 20240220

Year of fee payment: 11

Ref country code: NO

Payment date: 20240228

Year of fee payment: 11

Ref country code: IT

Payment date: 20240321

Year of fee payment: 11

Ref country code: HR

Payment date: 20240221

Year of fee payment: 11

Ref country code: FR

Payment date: 20240325

Year of fee payment: 11

Ref country code: DK

Payment date: 20240325

Year of fee payment: 11

Ref country code: BE

Payment date: 20240327

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240402

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240401

Year of fee payment: 11